BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 29
• 30
• 31

• Drug Development

  Novartis AG Release: Six-Year Pivotal Study Data Reinforce The Superiority Of Tasigna Over Gleevec In Newly-Diagnosed Patients With Ph+ CML

  December 9, 2014

   · 

  17 min read
• BioCapital

  ACC: Study Published In American Heart Association Journal Hypertension Will Inappropriately Concern And Confuse Consumers About Bpa And Increased Blood Pressure

  December 9, 2014

   · 

  3 min read
• Drug Development

  New Trial Initiated Evaluating Amgen’s Talimogene Laherparepvec In Combination With Merck & Co.'s Anti-PD-1 Therapy KEYTRUDA (Pembrolizumab) For Advanced Melanoma

  December 9, 2014

   · 

  12 min read
• Drug Development

  Pharmacyclics, Inc. Release: IMBRUVICA (ibrutinib) In Combination With Rituximab Data Shows Positive Benefit-Risk Profile In Hematologic Malignancy

  December 9, 2014

   · 

  13 min read
• Drug Development

  Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

  December 9, 2014

   · 

  16 min read
• Drug Development

  Pharmacyclics, Inc. Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL)

  December 9, 2014

   · 

  18 min read
• Drug Development

  Janssen Research & Development Release: IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival In Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation

  December 9, 2014

   · 

  14 min read
• Drug Development

  Pharmacyclics, Inc. Release: IMBRUVICA (ibrutinib) Data Demonstrates Safety And Durability Of Response At Two-Year Follow-Up In Mantle Cell Lymphoma

  December 9, 2014

   · 

  14 min read
• Drug Development

  Janssen Research & Development Release: IMBRUVICA (ibrutinib) Long-term Follow-up Data In Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive At Two Years

  December 9, 2014

   · 

  14 min read
• Drug Development

  CTI BioPharma Announces Presentation Of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance In FLT3-ITD Positive AML Cells

  December 9, 2014

   · 

  7 min read